Neuronetics (NASDAQ:STIM – Get Free Report) and Mobia Medical (NASDAQ:MOBI – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and target prices for Neuronetics and Mobia Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuronetics | 1 | 0 | 4 | 0 | 2.60 |
| Mobia Medical | 1 | 1 | 5 | 0 | 2.57 |
Neuronetics presently has a consensus price target of $4.67, indicating a potential upside of 85.92%. Mobia Medical has a consensus price target of $20.75, indicating a potential upside of 82.34%. Given Neuronetics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Neuronetics is more favorable than Mobia Medical.
Insider & Institutional Ownership
53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Neuronetics and Mobia Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuronetics | $155.10 million | 1.23 | -$39.00 million | ($0.44) | -5.70 |
| Mobia Medical | $45.28 million | 8.37 | -$46.50 million | ($20.18) | -0.56 |
Neuronetics has higher revenue and earnings than Mobia Medical. Neuronetics is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Neuronetics and Mobia Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuronetics | -19.62% | -125.11% | -22.15% |
| Mobia Medical | N/A | N/A | N/A |
Summary
Neuronetics beats Mobia Medical on 7 of the 13 factors compared between the two stocks.
About Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
About Mobia Medical
Mobia Medical Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc. is based in AUSTIN, Texas.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
